Hoca Emre, Cangir Bilal, Ahbab Süleyman, Şahin Seher İrem, Çiftçi Öztürk Ece, Urvasızoğlu Ayşe Öznur, Kalaycı Nilsu, Engin İsmail, Ataoğlu Hayriye Esra
Department of Internal Medicine, Haseki Training and Research Hospital, University of Health Sciences, Istanbul 34260, Turkey.
Department of Internal Medicine, Başakşehir Çam ve Sakura City Hospital, Istanbul 34480, Turkey.
Diagnostics (Basel). 2025 Aug 14;15(16):2045. doi: 10.3390/diagnostics15162045.
: Non-alcoholic fatty liver disease (NAFLD) is a global public health issue. Although liver biopsy remains the gold standard for diagnosing hepatosteatosis, its invasiveness, high cost, and associated risks limit its widespread use. Therefore, there is a need for reliable, non-invasive, and cost-effective biomarkers to aid in the early detection of NAFLD. Our objective was to determine the utility of the triglyceride (TG)-to-high-density-lipoprotein (HDL) ratio in predicting non-alcoholic fatty liver disease. : This retrospective cross-sectional study included 2588 patients who met the inclusion criteria. Demographic data and laboratory results were collected from electronic health records. Experienced radiologists performed abdominal ultrasonography to assess fatty liver according to the EASL 2021 criteria. The TG/HDL ratio and other non-invasive scores (APRI, FIB-4, ALT/AST, TG/glucose) were calculated. Early-stage disease was defined as grade 1 or grade 2 hepatosteatosis. : The TG/HDL ratio was significantly higher in NAFLD patients (AUROC: 0.682) and outperformed the other non-invasive indices. At the optimal cut-off value of 1.86, the sensitivity was 80.7%, and the specificity was 45.5%. The TG/HDL ratio correlated positively with markers of glycemic control, inflammation, and liver enzymes. : The TG/HDL ratio is an accessible and valuable parameter for predicting non-alcoholic fatty liver disease. It offers a non-invasive alternative to liver biopsy and potentially prevents complications from non-alcoholic fatty liver disease or diagnostic approaches.
非酒精性脂肪性肝病(NAFLD)是一个全球性的公共卫生问题。尽管肝活检仍是诊断肝脂肪变性的金标准,但其侵入性、高成本及相关风险限制了其广泛应用。因此,需要可靠、非侵入性且具有成本效益的生物标志物来辅助NAFLD的早期检测。我们的目的是确定甘油三酯(TG)与高密度脂蛋白(HDL)的比值在预测非酒精性脂肪性肝病中的效用。
这项回顾性横断面研究纳入了2588例符合纳入标准的患者。从电子健康记录中收集人口统计学数据和实验室结果。经验丰富的放射科医生根据欧洲肝脏研究学会(EASL)2021标准进行腹部超声检查以评估脂肪肝。计算TG/HDL比值和其他非侵入性评分(APRI、FIB-4、ALT/AST、TG/血糖)。早期疾病定义为1级或2级肝脂肪变性。
NAFLD患者的TG/HDL比值显著更高(曲线下面积:0.682),且优于其他非侵入性指标。在最佳截断值为1.86时,敏感性为80.7%,特异性为45.5%。TG/HDL比值与血糖控制、炎症和肝酶标志物呈正相关。
TG/HDL比值是预测非酒精性脂肪性肝病的一个易于获取且有价值的参数。它为肝活检提供了一种非侵入性替代方法,并有可能预防非酒精性脂肪性肝病的并发症或诊断方法。